2016 Fiscal Year Final Research Report
Glycotechnological development of a drug derived from urinastatin for the inhibition of premature delivery
| Project/Area Number |
26462470
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Hirosaki University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | ウリナスタチン / ヒアルロン酸 / プロテオグリカン / 糖鎖工学 / 早産 |
|---|
| Outline of Final Research Achievements |
The chondroitin sulfate chain of urinastatin, which is used as an anti-inflammatory medicine to inhibit premature delivery, was remodeled to hyaluronan to create hyaluronan hybrid urinastatin. Hyaluronan hybrid urinastatin inhibited protease (trypsin, plasmine, and elastase) and glycosidase (hyaluronidase) activity. Inhibition of the hyaluronan hybrid urinastatin toward the enzymes was similar though slightly weaker than the native urinastatin but stronger than the urinastatin without chondroitin sulfate chain nor hyaluronan, indicating the importance of the glycosaminoglycan chain and its sulfation. Further, experiments using cultured uterine cells showed that anti-inflammatory effects of the hyaluronan hybrid urinastatin were also similar to the native urinastatin. However, attractive interaction between hyaluronan hybrid urinastatin and phospholipid, abundant in the outer layer of the plasma membrane, was stronger than that of native urinastatin.
|
| Free Research Field |
糖鎖工学
|
